Oxford-AstraZeneca Covid vaccine shows robust immune response among older adults

Advertisement

BEGIN ARTICLE PREVIEW:

A Brazilian doctor voluntarily receives an injection as part of phase 3 trials of a vaccine developed by the University of Oxford and British pharmaceutical company AstraZeneca, in July 2020.Nelson Almeida | AFP | Getty ImagesLONDON — The coronavirus vaccine being developed by the University of Oxford and AstraZeneca is safe and triggers a similar immune response among all adults, according to the preliminary findings of a peer-reviewed phase two trial.The promising early-stage results were published Thursday in The Lancet, one of the world’s top medical journals.The study of 560 healthy adults, including 240 over age 70, found the vaccine to be safe and produced a similar immune response among people age over 56 and those ages 18 to 55.Older people face a “significant risk” of developing severe illness on contracting Covid-19, the WHO has said, citing decreased immune function and potential underlying health conditions. People of all ages are at risk of contracting the virus, however.AstraZeneca, which is working the University of Oxford, has previously said interim data showed their experimental vaccine had produced an immune response in older and younger adults.”We’re really delighted with the results,” professor Andrew Pollard, the head of Oxford’s vaccine trial team, told reporters Thursday.”In this study, we …

END ARTICLE PREVIEW

READ MORE FROM SOURCE ARTICLE